DEVICE COST-EFFECTIVENESS DATA CAN SPEED MEDICARE COVERAGE DECISIONS, HCFA STAFFER ACKNOWLEDGES; PROVIDING LIST OF EXPERTS IN TECHNOLOGY ALSO "VERY HELPFUL"
This article was originally published in The Gray Sheet
Executive SummaryMedical device cost-effectiveness data can speed up Medicare coverage decisions by the Health Care Financing Administration, Grant Bagley, HCFA director of coverage and analysis for clinical standards and quality, said Oct. 28 at a Health Industry Manufacturers Association meeting in Washington, D.C.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.